Van Hulzen Asset Management LLC Purchases New Holdings in Stryker Corporation $SYK

Van Hulzen Asset Management LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 15,148 shares of the medical technology company’s stock, valued at approximately $4,769,000.

A number of other institutional investors have also recently bought and sold shares of SYK. Veratis Advisors Inc. purchased a new position in shares of Stryker in the 2nd quarter worth about $312,000. Peak Asset Management LLC bought a new position in Stryker during the second quarter valued at about $16,476,000. Fiduciary Financial Advisors bought a new position in Stryker during the second quarter valued at about $851,000. L2 Asset Management LLC purchased a new stake in Stryker during the second quarter worth about $656,000. Finally, Vega Investment Solutions bought a new stake in Stryker in the second quarter worth about $93,000. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 355,370 shares of company stock worth $119,447,201 in the last 90 days. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Citigroup reiterated a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. Robert W. Baird set a $385.00 price target on Stryker in a research report on Friday, May 1st. BMO Capital Markets started coverage on shares of Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. Needham & Company LLC decreased their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Argus set a $370.00 price objective on shares of Stryker in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Trading Down 0.5%

NYSE SYK opened at $327.80 on Tuesday. The stock has a market cap of $125.73 billion, a P/E ratio of 33.97, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The stock has a 50 day simple moving average of $327.39 and a two-hundred day simple moving average of $332.16. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.